The precise mechanism by which COVID-19 may induce angioedema remains unclear, but potential pathways include the interplay between ACE and bradykinin (Figure 1). ACE inhibitor-induced angioedema is believed to be mediated by increased bradykinin levels due to impaired breakdown by ACE [7,13,14]. Here, KNG1 is linked to COVID-19.